Where is the manufacturer of Ripretinib?

Ripretinib was originally developed and produced by Deciphera Pharmaceuticals, LLC, and is sold under the trade name QINLOCK after approval by the FDA. It improves the treatment of advanced gastrointestinal stromal tumors (GIST) patients by inhibiting all known mutations in KIT and PDGFRA. Ripretinib, the active ingredient in Ripretinib, blocks initiating and resistance KIT mutations in exons 9, 11, 13, 14, 17 and 18 known to be present in GIST patients.

While approved kinase inhibitors control certain resistance-initiating and resistance-causing mutations in KIT and PDGFRA, the kinases that drive disease progression in the majority of patients with GIST, these approved drugs do not inhibit all known mutations. Repectinib similarly inhibits the initial PDGFRA mutations that occur in exons 12 and 18 and also inhibits wild-type PDGFRA that is amplified in cancer.

The original drug of Ripetinib has been marketed in China and has been approved by the National Medical Insurance Bureau to enter the scope of Class B medical insurance, but it is limited to patients who meet the indications. The price of each box of 50mg*30 tablets may be around 30,000 yuan. The expensive price may increase the pressure on families with heavy financial burdens. The US version of Ripetinib Specifications50mg*90 tablets sold overseas may be priced around RMB 77,000 per box (the price may fluctuate due to exchange rates). The ingredients of foreign original drugs are basically the same as those of domestic original drugs. Currently, there is no generic drug of Ripetinib produced and marketed overseas. For specific prices and drug information, please consult Yaode’s medical consultant.